azd-1208
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01489722)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase PIMINHIBITOR
Serine/threonine-protein kinase PIM inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC1CCCN(c2c(/C=C3/SC(=O)NC3=O)cccc2-c2ccccc2)C1- Mol. weight
- 379.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545423 ↗
Also known as
- 5-((2-((3r)-3-aminopiperidin-1-yl)biphenyl-3-yl)methylidene)-1,3-thiazolidine-2,4-dione
- azd1208
- azd1208
- azd1208
- azd 1208.
- azd-1208
- azd-1208
- azd-1208
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01588548 | Phase 1 | Jul 1, 2012 | AstraZeneca |
| NCT01489722 | Phase 1 | Feb 1, 2012 | AstraZeneca, Sponsor GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2012 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1